Last $4.05 USD
Change Today +0.20 / 5.19%
Volume 80.3K
CAPR On Other Exchanges
As of 8:10 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

capricor therapeutics inc (CAPR) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/27/14 - $15.00
52 Week Low
01/8/15 - $3.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

capricor therapeutics inc (CAPR) Related Businessweek News

No Related Businessweek News Found

capricor therapeutics inc (CAPR) Details

Capricor Therapeutics, Inc., a biotechnology company, is focused on the development of novel therapeutics to prevent and treat cardiovascular diseases. Its lead product candidates include CAP-1002 and Cenderitide. The company was founded in 2005 and is based in Beverly Hills, California.

19 Employees
Last Reported Date: 06/6/14
Founded in 2005

capricor therapeutics inc (CAPR) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $232.3K
Executive Vice President, General Counsel and...
Total Annual Compensation: $189.4K
Compensation as of Fiscal Year 2013.

capricor therapeutics inc (CAPR) Key Developments

Capricor Therapeutics Initiates the DYNAMIC Clinical Trial for the Treatment of Advanced Heart Failure

Capricor Therapeutics, Inc. announced that the first three patients have been treated in its DYNAMIC clinical trial. The trial is being conducted by Dr. Raj Makkar and his colleagues at Cedars-Sinai Heart Institute in Los Angeles. The Phase I DYNAMIC trial, also known as the 'Dilated cardiomYopathy iNtervention with Allogeneic MyocardIally-regenerative Cells' trial, will evaluate CDCs (CAP-1002) in patients with advanced heart failure. The Phase I trial is being funded in part through a grant of approximately $3 million from the National Institutes of Health (NIH). The Phase I trial will enroll 14 patients with either ischemic or non-ischemic dilated cardiomyopathy with left ventricular ejection fraction (LVEF) = 35% and New York Heart Association (NYHA) Class III or Ambulatory Class IV heart failure. Suitable patients will undergo sequential intracoronary infusion (triple vessel infusion) of CAP-1002 in up to three coronary territories. The primary safety endpoints will be assessed at the 1-month visit. Safety and exploratory efficacy endpoints including ejection fraction, ventricular volumes and a six-minute walk test will be evaluated at both the 6 and 12 month follow-up. It is hoped that following the successful 14 patient lead-in phase of DYNAMIC, the safety results will support continuation to a subsequent phase that includes a randomized, control cohort. Capricor is concurrently conducting the 300 patient, Phase II ALLSTAR trial with CAP-1002 in patients thirty days to one year following large myocardial infarctions (heart attack). ALLSTAR is designed to determine safety and effectiveness at scar size reduction of CAP-1002 in patients at high risk following myocardial infarction. Phase II of the ALLSTAR trial is being funded with the support of the California Institute for Regenerative Medicine.

Capricor Therapeutics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015

Capricor Therapeutics, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 . Venue: Westin St. Francis Hotel, San Francisco, California, United States.

Capricor Therapeutics, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 10:30 AM

Capricor Therapeutics, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 10:30 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CAPR:US $4.05 USD +0.20

CAPR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CAPR.
View Industry Companies

Industry Analysis


Industry Average

Valuation CAPR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAPRICOR THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at